作者: William B. Isaacs , Jianfeng Xu
DOI: 10.1016/J.AJUR.2018.10.001
关键词: Genetics 、 Genetic variants 、 Prostate cancer 、 Genetic profile 、 Germline 、 Medicine 、 Genetic predisposition 、 Standard of care 、 Genetic testing 、 Single-nucleotide polymorphism
摘要: Dramatic progress has been made in the area of germline genetics prostate cancer (PCa) past decade. Both common and rare genetic variants with effects on risk ranging from barely detectable to outright practice-changing have identified. For men high PCa, application testing for inherited pathogenic mutations is becoming standard care. A major question exists about which additional populations test, as at all levels can potentially benefit by knowing their unique profile susceptibility variants. This article will provide a brief overview some current issues understanding PCa.